cladribine has been researched along with Cancer of Spleen in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cecconi, N; Cervetti, G; Galimberti, S; Ghio, F; Pelosini, M; Petrini, M | 1 |
| Adil, SN; Bilwani, F; Kakepoto, GN; Khurshid, M; Usman, M | 1 |
| Bauer, F; Beham-Schmid, C; Brezinschek, R; Jaeger, G; Mannhalter, C; Neumeister, P | 1 |
| Juneja, SK; Westerman, DA | 1 |
| François, S; Grosbois, B; Hermine, O; Lefrère, F; Misset, JL; Panelatti, G; Troussard, X; Valensi, F; Varet, B | 1 |
1 trial(s) available for cladribine and Cancer of Spleen
| Article | Year |
|---|---|
Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Splenic Neoplasms; Therapeutic Equivalency; Treatment Outcome | 2000 |
4 other study(ies) available for cladribine and Cancer of Spleen
| Article | Year |
|---|---|
Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Rituximab; Splenic Neoplasms; Treatment Outcome | 2013 |
Hairy cell leukemia: clinical presentation and long term follow up after treatment with 2-chlorodeoxyadenosine (2-CdA).
Topics: Adult; Antineoplastic Agents; Bone Marrow Neoplasms; Cladribine; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Retrospective Studies; Splenic Neoplasms; Time Factors | 2005 |
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Topics: Adult; Alemtuzumab; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Transfusion; Cladribine; Cyclophosphamide; Doxorubicin; Female; Humans; Liver Neoplasms; Lymphoma, T-Cell; Neutropenia; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Recurrence; Remission Induction; Rituximab; Splenic Neoplasms; Vincristine | 2008 |
Test and teach. Number one hundred and one: Part 1.
Topics: Aged; Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Cladribine; Diagnosis, Differential; Humans; Immunophenotyping; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemic Infiltration; Lymphoma; Male; Splenectomy; Splenic Neoplasms; Treatment Outcome | 2000 |